Sp1058
FAILURES AND SUCCESSES AMONG BIOIMARKERS FOR FUNCTIONAL DYSPEPSIA
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
Presenter
Tracks
Related Products
IS IT DYSPEPSIA OR GASTROPARESIS
Back by popular demand, the experts will share and debate the evidence and their approaches to chronic pain, defecatory disorders, dyspepsia. and gastroparesis…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
LOCAL GASTROINTESTINAL REACTIONS TO FOOD IN DGBI
A session focusing on recent advances in our understanding of the complex pathophysiology of disorders of gut-brain interaction (DGBI)…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
